Skip to main content
Stephen Ringle

Stephen Ringle

Founder & CEO of Nome, an AI-enabled techbio building custom therapeutics for ultra-rare diseases, and founder of the Kizuna Foundation; rare disease patient advocate.

Sep 24, 2026

18:28
Can you walk us through a specific patient journey with Nome from genetic diagnosis to a, a treatment plan and, and into manufacturing and clinical execution? What, what's the process? What does that look like?
18:40
A lot of times it starts with listening to something just like this.
18:43
We get lots of patients that have heard about Nome online in some way.
18:49
They go on our website, which is www.nome.bio, and they submit their genetic information and as much clinical detail as they, as they can.
18:58
Uh, and what we do is we, we take that in.
19:00
We're, we're HIPAA compliant, so, you know, all the data is highly protected.
19:04
We process it in the type of report that I was sharing with you that has these, um, tiered insights about what might be appropriate for that family.
23:08
A-and in terms of your customers, are they generally individual families, or are, are they patient organizations, and how do you get paid?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.